- Global Pharma News & Resources

Preimplantation Genetic Testing Market exhibiting CAGR of 9% between 2023 to 2032, owing to increasing demand for better health screening | insightSLICE

The global Preimplantation Genetic Testing market size was estimated to be US$ 504 million in 2021 and is expected grow at a CAGR of 9% between 2023 to 2032.

Preimplantation Genetic Testing utilizes genetic diagnosis methods to enable early detection of genetic defects during IVF treatment to select healthy embryos for implantation. Because preimplantation genetic testing is specifically used for embryos generated through in vitro fertilization (IVF) its rise is directly linked to this sector as well.

Access the sample report:

Global Preimplantation Genetic Testing Market Key Segments:

By Types

  • Preimplantation Genetic Testing
  • Preimplantation Genetic diagnosis

By Technology

  • Next-Generation Sequencing
  • Comparative Genomic Hybridization
  • Single-Nucleotide Polymorphism
  • Validation Biomarkers
  • Fluorescence in Situ Hybridization
  • Polymerase Chain Reaction

By Application

  • Single Gene Disorders
  • X-Linked Disorders
  • Aneuploidy
  • Structural Chromosomal Abnormalities
  • HLA Typing

By Product and Service

  • Instruments
  • Reagents and Consumables
  • Software and Services

By End-users

  • Hospitals, Diagnostic Labs, and Service Providers
  • Maternity Centers & Fertility Clinics
  • Research Laboratories & Academic Institutes

By Geography

  • North America
    • United States
    • Canada
    • Rest of North America
  • Europe
    • Germany
    • United Kingdom
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • India
    • China
    • Australia
    • Rest of Asia Pacific
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Rest of the Middle East & Africa
  • South America
    • Brazil
    • Rest of South America

This service has become a very important step in IVF and is also highly demanded detection of expected or unknown defects before implanting the embryo for further pregnancy procedures. The genetic detection of such diseases increases the likelihood of safe and healthy birth. This is done by actively selecting defect-free IVF-derived embryos from a larger set.

Preimplantation genetic testing helps in the prevention of unknown hereditary diseases to be inherited by children conceived through IVF. It also prevents any developmental defects present in embryos from proliferating ahead of the embryo stage.

IVF procedure consists of the collection of eggs from egg donors, in vitro fertilization, culturing embryos, selecting viable embryos, and implantation in the uterus of the mother. Within this procedure, preimplantation genetic testing is done post-fertilization and before selecting the embryo for implantation.

All the embryos that are deemed healthy are frozen and stored for further implantation process whereas unfit embryos are generally destroyed. Preimplantation genetic testing is also being utilized for determining other characteristics like gender or physical features of the embryo in certain cases.

The IVF and artificial insemination procedures, even though being perfected, have a significant chance of failure, stillbirth, or malformations. Early detection methods are necessary and therefore are being demanded by the patients and clinicians involved in artificial insemination methods. Preimplantation genetic testing ensures malformations or health difficulties in babies are detected before being conceived.

Cystic fibrosis, congenital heart diseases, thalassemia, rare developmental defects as well as many other diseases have been successfully detected by use of preimplantation genetic testing. This technique is very useful in case the parents have known genetic defects as it helps select embryos free of these defects.

Read more about the report inclusions:

Preimplantation genetic testing is mostly done in tandem with the genetic screening of parents or donors ensuring genetic compatibility as well. Governmental organizations, NGOs, and regulatory bodies are in support of this service as it enables earlier detection of diseases and helps expecting parents.

Statistics suggest that many kids, especially the ones born through the IVF technique are more susceptible to congenital birth defects and they are therefore the primary drivers.

Point mutations, CAG repeat defects, and mitochondrial defects can be detected through preimplantation genetic testing techniques. Because carriers of genetic defects, single gene donors, and older couples seeking pregnancy are prone to defective childbirths and this benefits the most it.

The key players of the Global Preimplantation Genetic Testing Market are:

Companies that are currently leading the preimplantation genetic testing market are Illumina, Inc., Abbott Laboratories, Agilent Technologies, Inc., PerkinElmer, Inc., Oxford Gene Technology, Yikon Genomics, and SciGene Corporations.

Driving factors for the growth of Global Preimplantation Genetic Testing Market

This sector is seeing increased demand due to better adoption of IVF services, rising demand for better health screening, and a higher rate of income for expecting parents. The rise in demand for preimplantation genetic testing services is also supported by technological advances in genetics, bioinformatics, big data processing, and diagnostic tools.

Further enhancement of demand is expected due to medical research, upscaling of genetic testing processes, and increasing knowledge of the human genome. Additionally, legislation and support from governmental and regulatory bodies for genetic screening and the general outlook of the populace for genetic testing methods are helping spur the adoption of such services by the masses.

All these features are helping to gather the investment and interest of big pharmaceutical companies in the preimplantation genetic testing market.

Related reports:

Global Molecular Spectroscopy Market:

Global Transport Patient Monitor Market:

Regional performance of Preimplantation Genetic Testing Market

North America and Western Europe are leading the market for preimplantation genetic testing across the globe. These regions will further drive this sector in the upcoming years. The emerging market of Asia-Pacific will also see the use of preimplantation genetic services increase with the increased adoption of IVF and genetic diagnosis techniques.

The overall population and development of economies will ensure a faster growth rate for the preimplantation genetic testing market in countries like China, Japan, the Philippines, and India once adoption occurs.

The expected growth will mostly be driven by couples seeking late pregnancies, pre-birth conditions determining demand, and decreasing the cost of these services because of the larger scale of the economy in these regions.

The North American market is specifically expected to see continued growth in the preimplantation genetic testing market. Growing access to advanced healthcare and increased disposable income are turning the Asia-Pacific region into a hotbed for this market.

Proceed to purchase:

insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details, please contact our research and consulting team at

Contact us:

Alex R

+1 707 736 6633

Linkedin | Twitter

Editor Details

Last Updated: 09-Nov-2022